Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
103.4 USD | +0.68% | -3.00% | +12.14% |
May. 14 | Stephens Starts Blueprint Medicines With Overweight Rating, $140 Price Target | MT |
May. 06 | Blueprint Medicines Insider Sold Shares Worth $1,050,000, According to a Recent SEC Filing | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.14% | 6.43B | |
+60.80% | 62.59B | |
-2.98% | 41.18B | |
+44.47% | 40.29B | |
-8.29% | 27.9B | |
+12.78% | 26.21B | |
-21.73% | 19.09B | |
+5.95% | 13.08B | |
+24.52% | 12.26B | |
+26.96% | 12.05B |
- Stock Market
- Equities
- BPMC Stock
- News Blueprint Medicines Corporation
- Wedbush Raises Blueprint Medicines' Price Target to $120 From $110 After Stronger-Than-Expected Q1 Results, Keeps Outperform Rating